Regenxbio Reports the Initiation of First Pivotal Program for RGX-314 to Treat Wet AMD

January 6, 2021 Auto Bot Clinical Trials, Regenxbio, Treat, Update, wet AMD 0

Shots:

  • Regenxbio has reported that the ATMOSPHERE trial evaluating RGX-314 is active and patient screening is ongoing. The study will enroll 300 patients across two RGX-314 dose arms vs ranibizumab, with anticipated initiation of patients dosing in Q1’21
  • The second trial is expected to be similar in design to ATMOSPHERE with its expected initiation in H1’21. The company expects to submit a BLA based on these trials in 2024
  • The company has completed enrollment of patients in Cohort 1 of the P-II AAVIATE study for wet AMD. Moreover, Regenxbio reported a new program RGX-202 for DMD with its expected IND filing in mid-2021

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: BioHealth Capital Region

The post Regenxbio Reports the Initiation of First Pivotal Program for RGX-314 to Treat Wet AMD first appeared on PharmaShots.